BioNTech Banks On Oncology Pipeline As COVID Cash Dries Up

Like rival Moderna, company reported a steep drop in revenue, but it is still prioritizing its COVID-19 vaccine as an investment priority, while also moving ahead with multiple deals with China-based firms.